Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Economia

COMUNICATO STAMPA - Responsabilità editoriale di Business Wire

OptraSCAN® Receives CE Mark Approval for In-Vitro Diagnostics Use

Business Wire

OptraSCAN®, the leading end-to-end digital pathology solution provider, today announced that their whole-slide scanners have received CE Mark approval for European Standards applicable to “In-Vitro Diagnostics Directive (IVDD)” 98/79/EC for in-vitro diagnostics use. The CE Mark will allow OptraSCAN’s scanners to be sold in countries belonging to or affiliated to European Union (EU) that recognizes CE Mark.

OptraSCAN’s On-Demand desktop scanning systems are cloud-enabled and provide the ultimate flexibility for storing, archiving and managing digital images and metadata. These small footprint, low and high throughput scanners are fully-integrated, affordable and lightweight that can easily fit into small workspaces.

“The CE Mark specifically addresses the safety, quality and performance of In-Vitro Diagnostic Directives (IVDDs) (98/79/EC), and certifies that it has been created and manufactured to meet strict safety and health criteria for distribution in the European Union (EU). We are very pleased to receive this approval as it underlines our commitment in providing robust, high-quality solutions to meet the needs of diverse healthcare providers in the EU and affiliated countries,” said Abhi Gholap, Founder & CEO.

He further added, “This is a significant milestone for OptraSCAN to support pathologists from the European continent towards adopting Digital Pathology for their requirements.”

About OptraSCAN:

OptraSCAN® (www.optrascan.com), ISO 13485 certified, is an end-to-end digital pathology solution provider. OptraSCAN is focused on delivering fully integrated, affordable solutions that will maximize your return on investment and improve the performance of your pathology services. OptraSCAN® is a pioneer in the On-Demand Digital Pathology® System and is working to eliminate the barriers to “Go Digital” no matter the size of the pathology lab, the lab's throughput or global location.

OptraSCAN’s end-to-end solution provides effective acquisition of whole slide images, viewing, storing, sharing, reporting, analysis and management of digital slides and associated metadata, via On-Demand solution or outright purchase model. Follow us on LinkedIn and Twitter.

OptraSCAN
Media Inquiries:
Shruti Soman | Manager – Marketing Communications | 91.20.66540900 x 231 | s.soman@optraventures.com
or
Europe Sales Inquiries:
Anand Maiskar | VP – Sales & Business Development | 91.20.66540900 x 203 | anand@optrascan.com

Permalink: http://www.businesswire.com/news/home/20180912005383/en

Video Economia


Vai al sito: Who's Who

Modifica consenso Cookie